News & Publications

Atavistik Bio Announces U.S. FDA Clearance of Investigational New Drug Application and Fast Track Designation for ATV-1601 for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)

Atavistik Bio Closes $40 Million Series B Extension for Advancement of its Pipeline Bringing Total Round Proceeds to $160 Million

Atavistik Bio Raises $120 Million Series B Financing to Advance the Development of Selective Allosteric Small Molecule Therapeutics for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and Myeloproliferative Neoplasms (MPNs)

Atavistik Bio to Present Discovery of JAK2 V617F Mutant-Selective Allosteric Inhibitors for the Treatment of Myeloproliferative Neoplasms (MPNs) at ASH 2025

Atavistik Bio Expands Leadership Team with Appointment of Susan Pandya, M.D., as Chief Medical Officer

Atavistik Bio Announces Appointment of William Sellers, M.D. to its Scientific Advisory Board

Atavistik Bio Announces Research Collaboration with Pfizer to Accelerate Discovery of Novel Precision Allosteric Therapeutics

Atavistik Bio Appoints Oncology Clinical Development Leader Mohammad Hirmand, M.D. to Board of Directors

Atavistik Bio Strengthens Leadership Team with Appointment of Paul Bruno, Ph.D. as Chief Business Officer

Atavistik Bio Raises Additional $40 Million to Advance Precision Allosteric Small Molecule Therapeutics

Atavistik Bio Appoints Bryan Stuart as Chief Executive Officer

Atavistik Bio Announces Publication in Science by Co-Founder Jared Rutter Describing Foundational Technology for its Atavistik Metabolite-Protein Screening (AMPS) Platform

Atavistik Bio Announces Collaboration with Plex Research to Enrich the Informatics Capabilities of its AMPS Platform and Accelerate the Discovery of Novel Small Molecule Therapeutics

Atavistik Bio Announces Formation of Scientific Advisory Board

Atavistik Bio Announces $60 Million Series A Financing to Advance Genetically-Validated Targets in Metabolic Diseases and Cancer